Literature DB >> 33291958

Prevalence of lifetime nonmedical opioid use among U.S. Health Center Patients aged 45 years and older with psychiatric disorders.

Jessica M Brooks1, Emre Umucu2, Karen L Fortuna3,4, M Carrington Reid5, Kathlene Tracy6, Lusine Poghosyan7.   

Abstract

OBJECTIVE: Despite recent concerns over the increase in opioid misuse among aging adults, little is known about the prevalence of lifetime nonmedical opioid use in underserved, vulnerable middle-aged and older patients with psychiatric disorders. This study aims to determine the lifetime prevalence of nonmedical opioid use among underserved, vulnerable U.S. adults aged ≥45 years with psychiatric disorders.
METHOD: A nationally representative sample (n = 3,294) was obtained from the 2014 Health Center Patient Survey which collects data on psychiatric disorders, opioid use, and other health information from underserved, vulnerable U.S. primary care populations. Predictor variables included self-reported panic disorder, generalized anxiety disorder, schizophrenia, or bipolar disorder. The outcome variable was self-reported lifetime nonmedical opioid use. Frequencies, counts, and unadjusted and adjusted logistic regression models were conducted with the cross-sectional survey dataset.
RESULTS: Patients with bipolar disorder had the highest lifetime nonmedical opioid use rate (20.8%), followed by schizophrenia (19.3%), panic disorder (16.5%), and generalized anxiety disorder (14.5%). Nonmedical opioid use was significantly associated with bipolar disorder (OR 3.46, 95% CI [1.33, 8.99]) and generalized anxiety disorder (OR 2.03 95% CI [1.08, 3.83]).
CONCLUSION: Our findings demonstrate a high prevalence of lifetime nonmedical opioid use in underserved, vulnerable middle-aged and older health center patients with psychiatric disorders. Given the prevalence, health center professionals should monitor, prevent, and treat new or reoccurring signs and symptoms of nonmedical opioid use in this high-risk group of aging patients with psychiatric disorders.

Entities:  

Keywords:  Opioids; epidemiology; geriatric psychiatry; geriatrics; health centers; primary care

Mesh:

Substances:

Year:  2020        PMID: 33291958      PMCID: PMC8187460          DOI: 10.1080/13607863.2020.1855105

Source DB:  PubMed          Journal:  Aging Ment Health        ISSN: 1360-7863            Impact factor:   3.658


  44 in total

1.  Trends in older adult nonmedical prescription drug use prevalence: Results from the 2002-2003 and 2012-2013 National Survey on Drug Use and Health.

Authors:  Ty S Schepis; Sean Esteban McCabe
Journal:  Addict Behav       Date:  2016-04-22       Impact factor: 3.913

Review 2.  Treatment for opioid use and outcomes in older adults: a systematic literature review.

Authors:  Anne Marie Carew; Catherine Comiskey
Journal:  Drug Alcohol Depend       Date:  2017-11-07       Impact factor: 4.492

3.  Comorbidity of severe psychotic disorders with measures of substance use.

Authors:  Sarah M Hartz; Carlos N Pato; Helena Medeiros; Patricia Cavazos-Rehg; Janet L Sobell; James A Knowles; Laura J Bierut; Michele T Pato
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

4.  Doctor-Diagnosed Arthritis and Self-Reported Physical Health Function Among Middle-Aged and Older Adults With Serious Mental Illness.

Authors:  Jessica M Brooks; Emre Umucu; Jennifer Sánchez; Carol Seehusen; Karen L Fortuna; Chungyi Chiu; Stephen J Bartels
Journal:  J Nerv Ment Dis       Date:  2019-11       Impact factor: 2.254

5.  Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.

Authors:  Thomas Kingsley Brown; Kenneth Alper
Journal:  Am J Drug Alcohol Abuse       Date:  2017-05-25       Impact factor: 3.829

6.  Symptoms of Depression Are Associated With Opioid Use Regardless of Pain Severity and Physical Functioning Among Treatment-Seeking Patients With Chronic Pain.

Authors:  Jenna Goesling; Matthew J Henry; Stephanie E Moser; Mohit Rastogi; Afton L Hassett; Daniel J Clauw; Chad M Brummett
Journal:  J Pain       Date:  2015-06-12       Impact factor: 5.820

Review 7.  Genetic and environmental influences on psychiatric comorbidity: a systematic review.

Authors:  M Cerdá; A Sagdeo; J Johnson; S Galea
Journal:  J Affect Disord       Date:  2009-12-11       Impact factor: 4.839

8.  Schizophrenia and Epigenetic Aging Biomarkers: Increased Mortality, Reduced Cancer Risk, and Unique Clozapine Effects.

Authors:  Albert T Higgins-Chen; Marco P Boks; Christiaan H Vinkers; René S Kahn; Morgan E Levine
Journal:  Biol Psychiatry       Date:  2020-02-08       Impact factor: 13.382

9.  A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder.

Authors:  Andrew S Huhn; Eric C Strain; D Andrew Tompkins; Kelly E Dunn
Journal:  Drug Alcohol Depend       Date:  2018-10-18       Impact factor: 4.492

10.  Substance use disorders in schizophrenia--clinical implications of comorbidity.

Authors:  Nora D Volkow
Journal:  Schizophr Bull       Date:  2009-03-26       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.